Sumary of Entyvio, Stelara plus immunomodulators not as effective for IBD:
- “When used with an immunomodulator (ie, azathioprine, methotrexate), anti-TNFs are associated with lower rates of anti-drug antibodies and increased rates of clinical remission but also with increased rates of infections,”.
- “[Entyvio (vedolizumab, Takeda)] and [Stelara (ustekinumab, Janssen)] are newer biologic therapies that do not seem to carry the same risk for infection as anti-TNFs or immunomodulators..
- A growing body of evidence also suggests that these newer biologics have lower rates of immunogenicity and are not necessarily more effective when used with an immunomodulator..
- Further prospective data are needed to determine efficacy and minimize risk for patients initiating combination therapy with vedolizumab or ustekinumab for IBD.”.
- TARGET-IBD was a longitudinal cohort study of 4,229 patients with IBD, including those with ulcerative colitis and Crohn disease..
- Lutz and colleagues collected data from electronic medical records for patients enrolled between July 2017 and November 2020..
- Researchers estimated the rates of anti-TNF, vedolizumab and ustekinumab monotherapy and combination therapy with methotrexate, azathioprine or mercaptopurine from at any time during study and at time of enrollment..
- Investigators stratified rates of combination therapy by time from drug approval and previous exposure to other biologic agents….